Cholesterol and ApoB: The Particles That Build Plaque Over a Lifetime
Blood lipids are not just a correlate of heart disease — the ApoB-carrying particles causally build arterial plaque over a lifetime. Here is what LDL, HDL, triglycerides and ApoB actually mean.
A cholesterol panel is one of the oldest routine blood tests, and one of the most consequential for long-term health. Cholesterol itself is essential — the body builds it into every cell membrane and uses it to make hormones. The risk comes not from cholesterol per se but from the particles that ferry it through the blood, and how many of them there are.
What the lipid numbers mean
A standard panel reports total cholesterol, LDL ('low-density lipoprotein') cholesterol, HDL ('high-density lipoprotein') cholesterol and triglycerides. LDL particles carry cholesterol out to the tissues; HDL carries it back. It is the LDL — and other apolipoprotein-B-containing particles — that can lodge in artery walls and seed plaque.
ApoB is a newer number worth knowing: exactly one ApoB protein rides on each atherogenic particle, so an ApoB measurement is essentially a direct count of the particles that cause plaque, rather than an estimate of the cholesterol they carry (Sniderman et al., 2019).
Why it is causal, not just correlated
For decades the LDL–heart-disease link could be dismissed as mere association. That case is now closed. Converging evidence from genetics (people born with lifelong low LDL have very low heart-disease rates), long-term observation, and randomised drug trials shows that LDL/ApoB particles cause atherosclerotic cardiovascular disease — a formal consensus of the European Atherosclerosis Society (Ference et al., 2017).
The effect is cumulative: it is the lifetime exposure — how high, for how long — that builds plaque, much like pack-years for smoking. This is why lowering LDL earlier and for longer yields more benefit than lowering it late.
Why ApoB may be the better number
LDL-cholesterol can understate risk in common situations — high triglycerides, diabetes, or many small dense LDL particles — where a 'normal' LDL-C still hides a high particle count. Because ApoB counts particles directly, it tends to predict cardiovascular risk at least as well as, and often better than, LDL-C or non-HDL cholesterol (Sniderman et al., 2011).
This is why lipid specialists increasingly favour ApoB (or non-HDL cholesterol as a cheaper stand-in) for judging risk, and modern guidelines list ApoB as a preferred measure especially when triglycerides are raised (Mach et al., 2020).
What actually lowers it
Diet and lifestyle move these numbers meaningfully: reducing saturated fat, adding soluble fibre, staying physically active, and reaching a healthy weight all lower LDL/ApoB, while regular activity and lower refined-carbohydrate intake improve triglycerides and HDL. For many people lifestyle alone is enough.
When risk is higher, LDL-lowering medication (statins first) is among the best-evidenced interventions in all of medicine: a large meta-analysis of over 170,000 people found that each reduction in LDL cut the rate of major vascular events proportionally, and safely (Cholesterol Treatment Trialists' Collaboration, 2010). The practical step is to get a lipid panel — ideally including ApoB — and discuss your target with a qualified professional, since the right goal depends on your overall risk.
References
Ference B.A. et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459–2472.
Sniderman A.D. et al. (2019). Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology, 4(12), 1287–1295.
Sniderman A.D. et al. (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337–345.
Cholesterol Treatment Trialists' (CTT) Collaboration (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376(9753), 1670–1681.
Mach F. et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111–188.
Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.
Read next
ExplainerMetabolismWhen fasting glucose and HbA1c disagree: why the two numbers diverge and what is checked next
A raised fasting glucose next to a normal HbA1c, or the reverse, does not by itself mean either result is wrong. The two tests reflect different things, and some conditions shift HbA1c without any change in blood sugar.
7 min read
ExplainerBiomarkersBody composition instead of weight: how it is measured, how accurate the methods are, and which numbers change decisions
BMI misses about half of people with excess body fat, different bioimpedance devices diverge from DXA by several percentage points, and DXA itself has day-to-day noise. Which body composition measurements actually change decisions — waist, a series on one device, strength before mass — and what is proven versus merely associated.
10 min read
ExplainerBiomarkersWalking speed: what counts as a meaningful change, and what the trials on speeding it up found
The thresholds for a meaningful change in walking speed — 0.05 and 0.10 m/s — were derived on groups, while the test's own error between two visits reaches 0.50 m/s. What is known about slowing and speeding up over time, what dual-task walking adds, and why the best trial in the field reduced mobility loss without ever separating from the control arm on the short speed test.
15 min read